Cytomegalovirus
Drug research and approvals for cytomegalovirus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 65 studies of cytomegalovirus are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, FDA has 8 approved and 14 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 65
- Trials authorized in Canada: 13
- FDA orphan approvals: 8
- EU medicines: 2
Recruiting Now
Newest start dates first, of 65 recruiting on ClinicalTrials.gov ↗- Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC…NCT07225972 · Phase 3 · New York Medical College · starts Sep 1, 2026
- CMV-CMI in csCMVi After HSCTNCT07688759 · Not reported · The First Affiliated Hospital of Soochow University · starts Jun 1, 2026
- Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory…NCT07679412 · Not applicable · LucasBio · starts Apr 27, 2026
- Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus InfectionNCT07635368 · Not reported · Copenhagen University Hospital, Rigshospitalet · starts Apr 21, 2026
- A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)NCT07199465 · Phase 1 · Merck Sharp & Dohme LLC · starts Mar 30, 2026
- Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCTNCT07511127 · Phase 3 · Ruijin Hospital · starts Feb 28, 2026
- Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral…NCT07685457 · Not applicable · LucasBio · starts Feb 10, 2026
- Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in…NCT07235683 · Phase 4 · University Health Network, Toronto · starts Dec 24, 2025
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveNCT07358910 · Not reported · Institut Pasteur du Cambodge · starts Dec 18, 2025
- Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV…NCT07670468 · Phase 1 / Phase 2 · LucasBio · starts Dec 4, 2025
Trials Authorized in Canada
The 10 newest of 13; search them all in Canada trials| Oct 21, 2025 | Clear-cmv: combination letermovir and standard of care antiviral for enhanced antiviral response in cytomegalovirus infection in lung transplant recipients: a…LETERMOVIR | UNIVERSITY HEALTH NETWORK | Pending |
| Aug 13, 2024 | Letermovir prophylaxis for cytomegalovirus in pediatric hematopoietic cell transplantationLETERMOVIR | CHILDRENS ONCOLOGY GROUP | Ongoing |
| Aug 10, 2022 | A phase 1/2a open-label dose-ranging and observer-blind placebo-controlled, safety and immunogenicity study of mrna-1647 cytomegalovirus vaccine in female and…MRNA-1647 | MODERNATX, INC. | Closed |
| Mar 2, 2022 | Influence of a 3-month letermovir treatment on gut inflammation in art-treated hiv-infected persons in an open labelled controlled randomized studyLETERMOVIR | DR JEAN-PIERRE ROUTY | Closed |
| Nov 5, 2021 | A phase 3, randomized, observer-blind, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of mrna-1647 cytomegalovirus (cmv) vaccine…MRNA-1647 | MODERNATX, INC. | Ongoing |
| Apr 21, 2021 | Randomized controlled trial of valganciclovir for cytomegalovirus infected hearing impaired infants (valear trial)VALGANCICLOVIR | CHILDRENS HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE | Pending |
| May 4, 2018 | Double-blind, randomized, placebo-controlled phase 2b, multi-center study to evaluate the safety, tolerability, efficacy and immunogenicity of a 2-dose and a…V160 (HUMAN CYTOMEGALOVIRUS [HCMV] VACCINE) / MAPA (MERCK ALUMINUM PHOSPHATE… | Merck & Co. (MSD) | Ongoing |
| Jun 6, 2017 | A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to…MARIBAVIR (SHP620)/ VALGANCICLOVIR | Takeda Pharmaceuticals USA | Ongoing |
| Dec 6, 2016 | A phase 3, multicenter, randomized, open-label, active-controlled study to assess the efficacy and safety of maribavir treatment compared to…MARIBAVIR (SHP620) | Takeda Pharmaceuticals USA | Closed |
| Dec 17, 2015 | A randomized, double-blind, multicenter, phase 3 study of the efficacy, safety, and tolerability of brincidofovir (bcv) versus valganciclovir (vgcv) for the…BRINCIDOFOVIR (CMX001) | Chimerix | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 22| Aug 30, 2024 | Prevymisprophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least… | Merck Sharp & Dohme LLC | Approved |
| Aug 30, 2024 | Prevymisprophylaxis of cytomegalovirus (CMV) disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are… | Merck Sharp & Dohme LLC | Approved |
| Jun 5, 2023 | Prevymisprophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV… | Merck Sharp & Dohme LLC | Approved |
| Nov 23, 2021 | LivtencityTreatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus… | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Nov 8, 2017 | PREVYMISProphylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem… | Merck Sharp & Dohme LLC | Approved |
| Dec 4, 1998 | CytoGam#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney… | CSL Behring LLC | Approved |
| Mar 4, 1996 | Vitrasert ImplantTreatment of CMV retinitis in patients with acquired immunodeficiency syndrome. | Bausch & Lomb Surgical, Chiron Vision Products | Approved |
| Jun 23, 1989 | CytoveneTreatment of cytomegalovirus retinitis in immunocompromised patients with AIDS. | Syntex (USA), Inc. | Approved |
| Jan 5, 2017 | cytomegalovirus specific cytotoxic T lymphocytesTreatment of cytomegalovirus infection in severely immunocompromised patients | ViraCyte, LLC | Designated |
| Nov 29, 2010 | filociclovirTreatment of active cytomegalovirus infections | Microbiotix, Inc. | Designated |
| Feb 1, 2007 | maribavirPrevention of cytomegalovirus viremia and disease in the populations at risk. | Takeda Pharmaceuticals U.S.A., Inc. | Designated |
| Dec 20, 2006 | Human cytomegalovirus immunoglobulinPrevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women | Biotest Pharmaceuticals Corporation's (BPC) | Designated |
| Jun 3, 2005 | Cytomegalovirus DNA vaccine with plasmids expressing pp65…Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell… | Astellas Pharma Global Development, Inc. | Designated |
| Nov 15, 1991 | Monoclonal antibody to cytomegalovirus (human)Treatment of cytomegalovirus retinitis in patients with AIDS. | Protein Design Labs, Inc. | Designated |
| Sep 13, 1991 | Monoclonal antibody to cytomegalovirus (human)Prophylaxis of cytomegalovirus disease in patients undergoing solid organ transplantation. | Protein Design Labs, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Nov 9, 2022 | Livtencitymaribavir · orphan | Takeda Pharmaceuticals International AG Ireland Branch | EMA ↗ |
| Jan 8, 2018 | Prevymisletermovir · orphan | Merck Sharp & Dohme B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA